Alteration of Cell Membrane Permeability by Cetyltrimethylammonium Chloride Induces Cell Death in Clinically Important Candida Species.

Publisher: MDPI Country of Publication: Switzerland NLM ID: 101238455 Publication Model: Electronic Cited Medium: Internet ISSN: 1660-4601 (Electronic) Linking ISSN: 16604601 NLM ISO Abbreviation: Int J Environ Res Public Health Subsets: MEDLINE

Original Publication: Basel : MDPI, c2004-

Candida*/physiology ; Disinfectants*/pharmacology; Humans ; Antifungal Agents/pharmacology ; Cetrimonium/pharmacology ; Cell Membrane Permeability ; Candida albicans ; Cell Death ; Microbial Sensitivity Tests

The increased incidence of healthcare-related Candida infection has necessitated the use of effective disinfectants/antiseptics in healthcare settings as a preventive measure to decontaminate the hospital environment and stop the persistent colonization of the offending pathogens. Quanternary ammonium surfactants (QASs), with their promising antimicrobial efficacy, are considered as intriguing and appealing candidates for disinfectants. From this perspective, the present study investigated the antifungal efficacy and action mechanism of the QAS cetyltrimethylammonium chloride (CTAC) against three clinically important Candida species: C. albicans, C. tropicalis, and C. glabrata. CTAC exhibited phenomenal antifungal activity against all tested Candida spp., with minimum inhibitory concentrations (MIC) and minimum fungicidal concentrations (MFC) between 2 and 8 µg/mL. The time−kill kinetics of CTAC (at 2XMIC) demonstrated that an exposure time of 2 h was required to kill 99.9% of the inoculums in all tested strains. An important observation was that CTAC treatment did not influence intracellular reactive oxygen species (ROS), signifying that its phenomenal anticandidal efficacy was not mediated via oxidative stress. In addition, sorbitol supplementation increased CTAC’s MIC values against all tested Candida strains by three times (8−32 μg/mL), indicating that CTAC’s possible antifungal activity involves fungus cell membrane destruction. Interestingly, the increased fluorescence intensity of CTAC-treated cells in both propidium iodide (PI) and DAPI staining assays indicated the impairment of cell plasma membrane and nuclear membrane integrity by CTAC, respectively. Additionally, CTAC at MIC and 2XMIC was sufficient (>80%) to disrupt the mature biofilms of all tested spp., and it inhibited the yeast-to-hyphae transition at sub-MIC in C. albicans. Finally, the non-hemolytic activity of CTAC (upto 32 µg/mL) in human blood cells and HBECs signified its non-toxic nature at the investigated concentrations. Furthermore, thymol and citral, two phytocompounds, together with CTAC, showed synergistic fungicidal effectiveness against C. albicans planktonic cells. Altogether, the data of the present study appreciably broaden our understanding of the antifungal action mechanism of CTAC and support its future translation as a potential disinfectant against Candida-associated healthcare infections.

Risk Manag Healthc Policy. 2020 Sep 28;13:1765-1780. (PMID: 33061710)
Adv Pharmacol Pharm Sci. 2022 Apr 14;2022:6626834. (PMID: 35464619)
PLoS One. 2012;7(3):e32952. (PMID: 22396802)
Pharm Biol. 2012 Dec;50(12):1536-41. (PMID: 23116193)
Prog Polym Sci. 2017 Aug;71:53-90. (PMID: 32287485)
Mycopathologia. 2011 Feb;171(2):93-101. (PMID: 20680686)
BMC Complement Altern Med. 2015 Nov 24;15:417. (PMID: 26601661)
Indian J Exp Biol. 2013 Jul;51(7):515-21. (PMID: 23898550)
Braz J Infect Dis. 2008 Feb;12(1):63-6. (PMID: 18553017)
Pan Afr Med J. 2014 Dec 22;19:398. (PMID: 25995794)
RSC Adv. 2020 Apr 30;10(29):17050-17057. (PMID: 35496920)
Sci Total Environ. 2015 Jun 15;518-519:352-62. (PMID: 25770948)
Sci Rep. 2019 Apr 24;9(1):6483. (PMID: 31019274)
Chem Biol Interact. 2019 Aug 1;308:294-303. (PMID: 31158333)
Antimicrob Resist Infect Control. 2018 Mar 27;7:45. (PMID: 29599969)
J Appl Microbiol. 2011 Feb;110(2):568-79. (PMID: 21176007)
J Appl Microbiol. 2000 Sep;89(3):397-403. (PMID: 11021571)
Indian J Crit Care Med. 2021 Oct;25(10):1207-1208. (PMID: 34916760)
Front Med (Lausanne). 2018 Feb 13;5:28. (PMID: 29487851)
Evid Based Complement Alternat Med. 2014;2014:378280. (PMID: 25250053)
J Bacteriol. 2001 Sep;183(18):5385-94. (PMID: 11514524)
Sci Rep. 2021 Apr 26;11(1):8896. (PMID: 33903615)
J Toxicol Sci. 2014 Apr;39(2):211-5. (PMID: 24646701)
ACS Infect Dis. 2015 Jul 10;1(7):288-303. (PMID: 27622819)
Cold Spring Harb Perspect Med. 2014 May 01;4(5):. (PMID: 24789878)
Front Cell Infect Microbiol. 2022 Jan 19;11:780545. (PMID: 35127553)
Front Cell Infect Microbiol. 2019 Jan 04;8:445. (PMID: 30662877)
Virulence. 2015;6(4):362-71. (PMID: 26048362)
Chem Phys Lipids. 2002 Oct;119(1-2):1-11. (PMID: 12270668)
Virulence. 2013 Feb 15;4(2):119-28. (PMID: 23302789)
Expert Rev Anti Infect Ther. 2013 May;11(5):523-35. (PMID: 23627858)
Chem Biol Interact. 2015 Feb 5;227:1-6. (PMID: 25523088)
Mycopathologia. 2007 Mar;163(3):137-43. (PMID: 17356790)
Med Mycol. 2015 Apr;53(3):275-84. (PMID: 25480017)
Sci Rep. 2017 Jul 18;7(1):5692. (PMID: 28720834)
Front Microbiol. 2018 Jul 18;9:1594. (PMID: 30072969)
Mycopathologia. 2016 Apr;181(3-4):225-33. (PMID: 26612621)
J Surfactants Deterg. 2019 Sep;22(5):1119-1127. (PMID: 32336911)
Antimicrob Agents Chemother. 2013 Jan;57(1):326-32. (PMID: 23114781)
Microbiol Mol Biol Rev. 2010 Sep;74(3):417-33. (PMID: 20805405)
J Biomol Struct Dyn. 2022 Oct;40(17):7762-7778. (PMID: 33754947)
Int J Environ Health Res. 2021 Jun;31(4):401-420. (PMID: 31509014)
Microbes Infect. 2016 May;18(5):310-21. (PMID: 26806384)
Curr Med Mycol. 2021 Sep;7(3):18-21. (PMID: 35528623)
Sci Rep. 2021 Oct 26;11(1):21049. (PMID: 34702898)
Biochim Biophys Acta Biomembr. 2017 Jul;1859(7):1254-1262. (PMID: 28414038)
Nanomaterials (Basel). 2020 Jun 05;10(6):. (PMID: 32517070)
BMC Infect Dis. 2015 Feb 28;15:108. (PMID: 25888031)
Can J Infect Dis Med Microbiol. 2021 Dec 20;2021:8658600. (PMID: 34966471)
J Antimicrob Chemother. 2006 Oct;58(4):760-7. (PMID: 16885181)
Front Microbiol. 2018 Nov 26;9:2835. (PMID: 30534118)

Keywords: CTAC; Candida albicans; clinical biofilms; disinfectant; fungal infections

0 (Antifungal Agents)
Z7FF1XKL7A (Cetrimonium)
0 (Disinfectants)

Date Created: 20230108 Date Completed: 20230110 Latest Revision: 20230313

20231215

PMC9819714

10.3390/ijerph20010027

36612353